Moleculin Biotech Inc. (NASDAQ: MBRX) shares absolutely exploded on Wednesday after the company gave an update on its coronavirus treatment. Specifically, the company announced that independent research found 2-deoxy-D-glucose (2-DG) to reduce replication of SARS-CoV-2, the virus that causes COVID-19, by 100% in in vitro testing.
Essentially, the company reported that inhibiting glycolysis with non-toxic concentrations of 2-DG completely prevented SARS-CoV–2 replication in Caco–2 cells.
Some quick background: Glycolysis is a process wherein cells convert glucose into energy and infected (host) cells are induced by viruses to increase dramatically their dependence on glycolysis. 2-DG inhibits glycolysis because, although it appears to cells to be glucose, it is in fact a decoy that cannot be converted into energy.
Moleculin’s drug candidate, WP1122, is referred to as a “prodrug” of 2-DG in which chemical elements are added to 2-DG to improve its delivery in vivo.
Dr. Don Picker, chief science officer of Moleculin, further commented:
2-DG is what we call the ‘active moiety’ in WP1122. The problem with 2-DG is that it is metabolized by the body too quickly, so you can’t get enough concentration in human tissues and organs to be therapeutic. Therefore, even though 2-DG is active against a range of viruses, including SARS-CoV-2, it isn’t useful as a clinical therapy because it’s too rapidly metabolized. WP1122 appears to solve this problem because it is a ‘prodrug’ of 2-DG. Its structure enables it to achieve much higher tissue/organ concentrations than 2-DG alone, but once it’s in the cell, it metabolizes into the exact same 2-DG that is so effective in vitro.
Moleculin stock traded up on Wednesday about 180% to $1.58, in a 52-week range of $0.32 to $3.15. The consensus price target is $3.33.
Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
